Asia Pacific Stroke Management Market Size to register a growth of 8.2% CAGR

20-11-2018 | Report Format: Electronic (PDF)

Growth, Trends and Report Highlights

According to a new report Asia Pacific Stroke Management Market, published by KBV research, the Asia Pacific Stroke Management Market would witness market growth of 8.2% CAGR during the forecast period (2018 – 2024).

The Japan market would dominate the Asia Pacific Diagnostics Stroke Management Market by Country by 2024, growing at a CAGR of 5.6 % during the forecast period. The China market is expected to witness a CAGR of 8% during (2018 - 2024). Additionally, The India market is expected to witness a CAGR of 9% during (2018 - 2024).

The Ischemic Stroke market dominated the Asia Pacific Stroke Management Market by Application 2017, and would acieve a market value of $6,946.2 million by 2024, growing at a CAGR of 6.6 % during the forecast period. The Haemorrhagic Stroke market is expected to witness a CAGR of 11.5% during (2018 - 2024).

Full Report: https://www.kbvresearch.com/asia-pacific-stroke-management-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of ABBOTT Laboratories, B. Braun Melsungen Ag, Boston Scientific Corporation, Cardinal Health, Inc., Ge Healthcare, Glaxosmithkline Plc, Medtronic Plc., Siemens Aktiengesellschaft, Merck & Co., Inc., and Bristol-Myers Squibb Company.